Alprazolam (Xanax): Uses, Risks, Dependence, and Alternatives

Alprazolam (brand name: Xanax) is a benzodiazepine (short-acting). Alprazolam is a high-potency, short-acting benzodiazepine that enhances GABA-A receptor activity. Its rapid onset (15-30 minutes) and short half-life (6-12 hours) produce quick anxiety relief but also create a pattern of 'rebound anxiety' between doses that can drive dose escalation and dependence. This pharmacokinetic profile makes it one of the most dependence-prone benzodiazepines.

• Panic Disorder
• Generalized Anxiety Disorder (short-term)

Common off-label uses:

• Anticipatory anxiety
• Insomnia (though not recommended)
• Chemotherapy-induced nausea (adjunctive)
• Acute agitation

Anxiety: 0.25-0.5 mg three times daily. Panic disorder: 0.5-1 mg three times daily, up to 4-6 mg/day. Extended-release: 0.5-1 mg once daily. Start low, especially in elderly. Available in immediate-release tablets, extended-release tablets, and oral solution.

Rapid onset: 15-30 minutes. Peak effect: 1-2 hours. Duration: 4-6 hours (immediate-release).

• Sedation and drowsiness
• Impaired coordination
• Memory impairment (anterograde amnesia)
• Slurred speech
• Cognitive dulling
• Decreased libido
• Rebound anxiety between doses

• Rapid physical dependence (can develop within 2-4 weeks)
• Severe withdrawal (potentially fatal seizures)
• Respiratory depression with opioids (FDA black box warning)
• Disinhibition and paradoxical rage
• Increased fall risk
• Association with increased dementia risk (long-term use)

Potentially fatal with opioids and alcohol. CYP3A4 substrate — ketoconazole, itraconazole, and grapefruit juice increase levels significantly. Fluvoxamine and fluoxetine increase levels.

Category D. Associated with neonatal withdrawal and potential teratogenicity. Avoid during pregnancy.

Extremely difficult to discontinue after long-term use due to short half-life. Common strategy: cross-taper to long-acting benzodiazepine (diazepam or clonazepam) then slowly taper. Typical tapers last months. Withdrawal includes severe anxiety, insomnia, seizures, psychosis, and perceptual disturbances.